Korea’s ethical markets getting heated
Published: 2013-02-20 07:00:00
Updated: 2013-02-20 07:00:00
Competition is about to heat up in the domestic ethical drug markets, as Gilead Sciences’ Viread (tenofovir), Boehringer Ingelheim’s Trajenta (linagliptin) and AstraZeneca’s Brilinta (tigagrelor) are expanding their shares of the domestic drug markets dominated by foreign forerunners.
Market e...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.